GSK Plc Partners with Ochre Bio on Innovative RNA Therapeutics for Liver Diseases
- GSK Plc partners with Ochre Bio to advance RNA therapeutics targeting chronic liver diseases through innovative datasets.
- The collaboration will lead to a co-exclusive licensing agreement for proprietary human liver data to expedite treatment development.
- GSK aims to enhance understanding of human biology and therapeutic innovation through large-scale datasets and AI integration.
GSK and Ochre Bio Forge Groundbreaking Collaboration in RNA Therapeutics for Liver Diseases
GSK Plc solidifies its commitment to innovative healthcare solutions through a pivotal collaboration with biotechnology firm Ochre Bio. Announced on November 18, 2025, this partnership marks a significant leap in the development of RNA therapeutics specifically targeting chronic liver diseases. The collaboration produces two comprehensive datasets that are crucial for understanding the underlying mechanisms of liver diseases. The first dataset, derived from primary human hepatocytes, involves a systematic gene knockdown approach across multiple human donors, enabling researchers to profile the effects through advanced RNA sequencing. The second dataset emerges from perfused human donor livers, providing a detailed single-cell analysis of gene expression across various liver cell types.
The collaboration not only enhances GSK's research capabilities but also paves the way for future therapeutic breakthroughs. Following the research phase, GSK and Ochre Bio will enter into a multi-year co-exclusive licensing agreement that allows both entities to utilize the proprietary human liver data generated during their work. This agreement is expected to expedite the discovery and development of new treatments for liver diseases, which have long been under-researched and underserved in the pharmaceutical industry. Ochre Bio’s proprietary OBELiX software will play a critical role in integrating the datasets with disease atlases, facilitating causal mapping of gene functions to disease signatures across various pathways and cell types.
Quin Wills, CEO of Ochre Bio, stresses the importance of large-scale human datasets in unraveling the complexities of human disease biology. GSK’s Kaivan Khavandi echoes this sentiment, emphasizing how the collaboration enhances their understanding of human biology and aids in developing new medicines. The data generated from this collaboration will not only drive therapeutic innovation but also lay the groundwork for training artificial intelligence models to identify promising therapeutic targets. By merging machine learning with extensive human datasets and RNA chemistry, Ochre Bio and GSK aim to address the challenges posed by chronic liver conditions more effectively.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

